Cite
HARVARD Citation
Zhou, C. et al. (n.d.). 86P Efficacy and safety of IBI110 (anti-LAG-3 mAb) in combination with sintilimab (anti-PD-1 mAb) in advanced squamous non-small cell lung cancer (sqNSCLC): Updated results of the phase Ib study. Immuno-oncology technology. p. . [Online].